Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Identifieur interne : 007E32 ( Main/Exploration ); précédent : 007E31; suivant : 007E33Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Auteurs : M. Marre [Australie] ; J. Shaw [Australie] ; M. Br Ndle [Australie] ; W. M. W. Bebakar [Australie] ; N. A. Kamaruddin [Australie] ; J. Strand [Australie] ; M. Zdravkovic [Australie] ; T. D. Le Thi [Australie] ; S. Colagiuri [Australie]Source :
- Diabetic Medicine [ 0742-3071 ] ; 2009-03.
Descripteurs français
- Pascal (Inist)
- Agoniste, Amélioration, Analogue, Diabète de type 2, Dose journalière, Dérivé de la thiazolidinedione, Endocrinologie, Etat nutritionnel, Etude comparative, Glycémie, Homme, Hypoglycémiant, Incrétine, Liraglutide, Maladie métabolique, Peptidases, Peptide GLP1, Placebo, Plomb, Poids corporel, Rosiglitazone, Récepteur GLP-1, Surveillance.
- Wicri :
- topic : Diabète, Association européenne, Glucose, Homme, Plomb.
English descriptors
- KwdEn :
- Agonist, American diabetes association, Analog, Baseline, Black line, Blood pressure, Body mass index, Body weight, Clinical endocrinologists, Combination therapy, Comparative study, Daily dose, Diabetes, Diabetes care, Diabetes mellitus, Diabetic medicine, Diabeticmedicine, Dos, Endocrinology, European association, Exenatide, Fasting, Fasting plasma glucose, Glimepiride, Glimepiride monotherapy, Glucagon like peptide 1, Glucose, Glycaemic, Glycaemic control, Glycated haemoglobin, Glycemia, Grey line, Hba1c, Human, Human analogue, Hypoglycaemia, Hypoglycaemic episodes, Hypoglycemic agent, Improvement, Incretin, Journal compilation, Last observation, Lead, Lecture fees, Liraglutide, Marre, Metabolic diseases, Metformin, Minor hypoglycaemia, Monotherapy, Nordisk, Nutritional status, Pancreatic, Pancreatic function, Peptidases, Placebo, Postprandial plasma glucose, Previous treatment, Rosiglitazone, Significant differences, Study group, Sulphonylureas, Surveillance, Thiazolidinedione derivatives, Treatment differences, Treatment groups, Type 2 diabetes, Weight effects, Weight loss.
- Teeft :
- American diabetes association, Baseline, Black line, Blood pressure, Body mass index, Body weight, Clinical endocrinologists, Combination therapy, Diabetes, Diabetes care, Diabetes mellitus, Diabetic medicine, Diabeticmedicine, Dos, European association, Exenatide, Fasting, Fasting plasma glucose, Glimepiride, Glimepiride monotherapy, Glucose, Glycaemic, Glycaemic control, Glycated haemoglobin, Grey line, Hba1c, Human analogue, Hypoglycaemia, Hypoglycaemic episodes, Journal compilation, Last observation, Lecture fees, Liraglutide, Marre, Metformin, Minor hypoglycaemia, Monotherapy, Nordisk, Pancreatic, Pancreatic function, Placebo, Postprandial plasma glucose, Previous treatment, Rosiglitazone, Significant differences, Study group, Sulphonylureas, Treatment differences, Treatment groups, Weight effects, Weight loss.
Abstract
Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo (n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.
Url:
- https://api.istex.fr/document/5D1C5E0A9AA3323713F8940A437C40DABC0E7835/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176
DOI: 10.1111/j.1464-5491.2009.02666.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001164
- to stream Istex, to step Curation: 001164
- to stream Istex, to step Checkpoint: 000E69
- to stream Pmc, to step Corpus: 002402
- to stream Pmc, to step Curation: 002252
- to stream Pmc, to step Checkpoint: 002773
- to stream Ncbi, to step Merge: 000554
- to stream Ncbi, to step Curation: 000554
- to stream Ncbi, to step Checkpoint: 000554
- to stream Main, to step Merge: 008527
- to stream PascalFrancis, to step Corpus: 002E90
- to stream PascalFrancis, to step Curation: 003130
- to stream PascalFrancis, to step Checkpoint: 002A27
- to stream Main, to step Merge: 008996
- to stream Main, to step Curation: 007E32
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)</title><author><name sortKey="Marre, M" sort="Marre, M" uniqKey="Marre M" first="M." last="Marre">M. Marre</name></author><author><name sortKey="Shaw, J" sort="Shaw, J" uniqKey="Shaw J" first="J." last="Shaw">J. Shaw</name></author><author><name sortKey="Br Ndle, M" sort="Br Ndle, M" uniqKey="Br Ndle M" first="M." last="Br Ndle">M. Br Ndle</name></author><author><name sortKey="Bebakar, W M W" sort="Bebakar, W M W" uniqKey="Bebakar W" first="W. M. W." last="Bebakar">W. M. W. Bebakar</name></author><author><name sortKey="Kamaruddin, N A" sort="Kamaruddin, N A" uniqKey="Kamaruddin N" first="N. A." last="Kamaruddin">N. A. Kamaruddin</name></author><author><name sortKey="Strand, J" sort="Strand, J" uniqKey="Strand J" first="J." last="Strand">J. Strand</name></author><author><name sortKey="Zdravkovic, M" sort="Zdravkovic, M" uniqKey="Zdravkovic M" first="M." last="Zdravkovic">M. Zdravkovic</name></author><author><name sortKey="Le Thi, T D" sort="Le Thi, T D" uniqKey="Le Thi T" first="T. D." last="Le Thi">T. D. Le Thi</name></author><author><name sortKey="Colagiuri, S" sort="Colagiuri, S" uniqKey="Colagiuri S" first="S." last="Colagiuri">S. Colagiuri</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5D1C5E0A9AA3323713F8940A437C40DABC0E7835</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1464-5491.2009.02666.x</idno><idno type="url">https://api.istex.fr/document/5D1C5E0A9AA3323713F8940A437C40DABC0E7835/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001164</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001164</idno><idno type="wicri:Area/Istex/Curation">001164</idno><idno type="wicri:Area/Istex/Checkpoint">000E69</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E69</idno><idno type="wicri:doubleKey">0742-3071:2009:Marre M:liraglutide:a:once</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871176</idno><idno type="RBID">PMC:2871176</idno><idno type="wicri:Area/Pmc/Corpus">002402</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002402</idno><idno type="wicri:Area/Pmc/Curation">002252</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002252</idno><idno type="wicri:Area/Pmc/Checkpoint">002773</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002773</idno><idno type="wicri:Area/Ncbi/Merge">000554</idno><idno type="wicri:Area/Ncbi/Curation">000554</idno><idno type="wicri:Area/Ncbi/Checkpoint">000554</idno><idno type="wicri:doubleKey">0742-3071:2009:Marre M:liraglutide:a:once</idno><idno type="wicri:Area/Main/Merge">008527</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0162156</idno><idno type="wicri:Area/PascalFrancis/Corpus">002E90</idno><idno type="wicri:Area/PascalFrancis/Curation">003130</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002A27</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002A27</idno><idno type="wicri:doubleKey">0742-3071:2009:Marre M:liraglutide:a:once</idno><idno type="wicri:Area/Main/Merge">008996</idno><idno type="wicri:Area/Main/Curation">007E32</idno><idno type="wicri:Area/Main/Exploration">007E32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)</title><author><name sortKey="Marre, M" sort="Marre, M" uniqKey="Marre M" first="M." last="Marre">M. Marre</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Shaw, J" sort="Shaw, J" uniqKey="Shaw J" first="J." last="Shaw">J. Shaw</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Br Ndle, M" sort="Br Ndle, M" uniqKey="Br Ndle M" first="M." last="Br Ndle">M. Br Ndle</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Bebakar, W M W" sort="Bebakar, W M W" uniqKey="Bebakar W" first="W. M. W." last="Bebakar">W. M. W. Bebakar</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Kamaruddin, N A" sort="Kamaruddin, N A" uniqKey="Kamaruddin N" first="N. A." last="Kamaruddin">N. A. Kamaruddin</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Strand, J" sort="Strand, J" uniqKey="Strand J" first="J." last="Strand">J. Strand</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Zdravkovic, M" sort="Zdravkovic, M" uniqKey="Zdravkovic M" first="M." last="Zdravkovic">M. Zdravkovic</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Le Thi, T D" sort="Le Thi, T D" uniqKey="Le Thi T" first="T. D." last="Le Thi">T. D. Le Thi</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Colagiuri, S" sort="Colagiuri, S" uniqKey="Colagiuri S" first="S." last="Colagiuri">S. Colagiuri</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Service d’Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat—Claude Bernard, Paris, France, *International Diabetes Institute, Melbourne, Australia, †Division of Endocrinology, Diabetes and Osteology, Kantonsspital St Gallen, Switzerland, ‡Department of Medicine, Hospital Universiti Sains, Malaysia, Kelantan, §Department of Medicine, National University of Malaysia (UKM), Kuala Lumpur, Malaysia, ¶Oulun Diakonissalaitos, Oulu, Finland, **Novo Nordisk A/S, Bagsvaerd, Denmark and ††Institute of Obesity, Nutrition and Exercise, University of Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Diabetic Medicine</title><title level="j" type="alt">DIABETIC MEDICINE</title><idno type="ISSN">0742-3071</idno><idno type="eISSN">1464-5491</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="268">268</biblScope><biblScope unit="page" to="278">278</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-03">2009-03</date></imprint><idno type="ISSN">0742-3071</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0742-3071</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>American diabetes association</term><term>Analog</term><term>Baseline</term><term>Black line</term><term>Blood pressure</term><term>Body mass index</term><term>Body weight</term><term>Clinical endocrinologists</term><term>Combination therapy</term><term>Comparative study</term><term>Daily dose</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetic medicine</term><term>Diabeticmedicine</term><term>Dos</term><term>Endocrinology</term><term>European association</term><term>Exenatide</term><term>Fasting</term><term>Fasting plasma glucose</term><term>Glimepiride</term><term>Glimepiride monotherapy</term><term>Glucagon like peptide 1</term><term>Glucose</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycated haemoglobin</term><term>Glycemia</term><term>Grey line</term><term>Hba1c</term><term>Human</term><term>Human analogue</term><term>Hypoglycaemia</term><term>Hypoglycaemic episodes</term><term>Hypoglycemic agent</term><term>Improvement</term><term>Incretin</term><term>Journal compilation</term><term>Last observation</term><term>Lead</term><term>Lecture fees</term><term>Liraglutide</term><term>Marre</term><term>Metabolic diseases</term><term>Metformin</term><term>Minor hypoglycaemia</term><term>Monotherapy</term><term>Nordisk</term><term>Nutritional status</term><term>Pancreatic</term><term>Pancreatic function</term><term>Peptidases</term><term>Placebo</term><term>Postprandial plasma glucose</term><term>Previous treatment</term><term>Rosiglitazone</term><term>Significant differences</term><term>Study group</term><term>Sulphonylureas</term><term>Surveillance</term><term>Thiazolidinedione derivatives</term><term>Treatment differences</term><term>Treatment groups</term><term>Type 2 diabetes</term><term>Weight effects</term><term>Weight loss</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Amélioration</term><term>Analogue</term><term>Diabète de type 2</term><term>Dose journalière</term><term>Dérivé de la thiazolidinedione</term><term>Endocrinologie</term><term>Etat nutritionnel</term><term>Etude comparative</term><term>Glycémie</term><term>Homme</term><term>Hypoglycémiant</term><term>Incrétine</term><term>Liraglutide</term><term>Maladie métabolique</term><term>Peptidases</term><term>Peptide GLP1</term><term>Placebo</term><term>Plomb</term><term>Poids corporel</term><term>Rosiglitazone</term><term>Récepteur GLP-1</term><term>Surveillance</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>American diabetes association</term><term>Baseline</term><term>Black line</term><term>Blood pressure</term><term>Body mass index</term><term>Body weight</term><term>Clinical endocrinologists</term><term>Combination therapy</term><term>Diabetes</term><term>Diabetes care</term><term>Diabetes mellitus</term><term>Diabetic medicine</term><term>Diabeticmedicine</term><term>Dos</term><term>European association</term><term>Exenatide</term><term>Fasting</term><term>Fasting plasma glucose</term><term>Glimepiride</term><term>Glimepiride monotherapy</term><term>Glucose</term><term>Glycaemic</term><term>Glycaemic control</term><term>Glycated haemoglobin</term><term>Grey line</term><term>Hba1c</term><term>Human analogue</term><term>Hypoglycaemia</term><term>Hypoglycaemic episodes</term><term>Journal compilation</term><term>Last observation</term><term>Lecture fees</term><term>Liraglutide</term><term>Marre</term><term>Metformin</term><term>Minor hypoglycaemia</term><term>Monotherapy</term><term>Nordisk</term><term>Pancreatic</term><term>Pancreatic function</term><term>Placebo</term><term>Postprandial plasma glucose</term><term>Previous treatment</term><term>Rosiglitazone</term><term>Significant differences</term><term>Study group</term><term>Sulphonylureas</term><term>Treatment differences</term><term>Treatment groups</term><term>Weight effects</term><term>Weight loss</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Diabète</term><term>Association européenne</term><term>Glucose</term><term>Homme</term><term>Plomb</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo (n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.</div></front></TEI><affiliations><list><country><li>Australie</li></country><region><li>Nouvelle-Galles du Sud</li></region><settlement><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Marre, M" sort="Marre, M" uniqKey="Marre M" first="M." last="Marre">M. Marre</name></region><name sortKey="Bebakar, W M W" sort="Bebakar, W M W" uniqKey="Bebakar W" first="W. M. W." last="Bebakar">W. M. W. Bebakar</name><name sortKey="Br Ndle, M" sort="Br Ndle, M" uniqKey="Br Ndle M" first="M." last="Br Ndle">M. Br Ndle</name><name sortKey="Colagiuri, S" sort="Colagiuri, S" uniqKey="Colagiuri S" first="S." last="Colagiuri">S. Colagiuri</name><name sortKey="Kamaruddin, N A" sort="Kamaruddin, N A" uniqKey="Kamaruddin N" first="N. A." last="Kamaruddin">N. A. Kamaruddin</name><name sortKey="Le Thi, T D" sort="Le Thi, T D" uniqKey="Le Thi T" first="T. D." last="Le Thi">T. D. Le Thi</name><name sortKey="Shaw, J" sort="Shaw, J" uniqKey="Shaw J" first="J." last="Shaw">J. Shaw</name><name sortKey="Strand, J" sort="Strand, J" uniqKey="Strand J" first="J." last="Strand">J. Strand</name><name sortKey="Zdravkovic, M" sort="Zdravkovic, M" uniqKey="Zdravkovic M" first="M." last="Zdravkovic">M. Zdravkovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007E32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007E32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5D1C5E0A9AA3323713F8940A437C40DABC0E7835
|texte= Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
}}
| This area was generated with Dilib version V0.6.33. |  |